)
Combination creates a scaled U.S. advanced therapies CDMO with broader technical expertise and capabilities from early development through commercial supply.…
){kind=logo}
SAN DIEGO, Aug. 5, 2026 /PRNewswire/ -- NueCell Bio, a newly established cell therapy science and development services company that utilizes…
)
Clinically meaningful improvements in global IBS symptom severity observed as early as Week 1 and sustained through Week 7, with…
){kind=logo}
Phase 1b/2a study in cystic fibrosis remains on track for full enrollment by end of 2025 following positive interim analysis…
)
Kineticos Portfolio Company, Inceptor Bio, Announces First Patient Dosed in Clinical Trial of IB-T101 for Clear Cell Renal Cell Carcinoma…
Clarametyx Biosciences Announces Investment by Kineticos AMR Accelerator Fund COLUMBUS, Ohio – January 28, 2025 – Clarametyx Biosciences Inc. (“Clarametyx”), a clinical…
INCATE and Kineticos extend partnership to support startups combating Antimicrobial Resistance December 16, 2024 – INCATE (the INCubator for Antibacterial Therapies…
Kineticos Portfolio Company Inceptor Bio Announces Strategic Partnership for Next-Generation Solid Tumor CAR-T December 18, 2024 –Inceptor Bio, a leading…